Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 246-253

  Smith, Malcolm A ^a   Maris, John M ^b   Gorlick, Richard ^c   Kolb, E Anders ^d   Lock, Richard ^e   Carol, Hernan ^e   Keir, Stephen T ^f   Reynolds, C Patrick ^g   Kang, Min H ^g   Morton, Christopher L ^h   Wu, Jianrong ^h   Smith, Peter G ⁱ   Yu, Jie ⁱ   Houghton, Peter J ^j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Developmental therapeutics; MLN4924; Preclinical testing

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; NEDD8 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; EWING SARCOMA; FEMALE; GLIOBLASTOMA; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT DURATION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CYCLOPENTANES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; NEUROBLASTOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; SARCOMA; TUMOR CELLS, CULTURED; UBIQUITINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862269352     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23357     Document Type: Article

References (32)

1. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010; 37: 102-111.
2. Milhollen MA, Narayanan U, Soucy TA, et al. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011; 71: 3042-3051.
3. Lin JJ, Milhollen MA, Smith PG, et al. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-10320.
4. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
5. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-κB-dependent lymphoma. Blood 2010; 116: 1515-1523.
6. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
7. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50: 37-45.
8. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharmaceut Statist 2011; 10: 128-134.
9. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-4195.
10. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006; 12: 223-234.
11. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005; 11: 6950-6958.
12. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
13. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
14. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-3800.
15. Kordes U, Krappmann D, Heissmeyer V, et al. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
16. Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.
17. Tsunoda K, Kitange G, Anda T, et al. Expression of the constitutively activated RelA/NF-κB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Brain Tumor Pathol 2005; 22: 79-87.
18. Wang H, Wang H, Zhang W, et al. Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas. Lab Invest 2004; 84: 941-951.
19. Korkolopoulou P, Levidou G, Saetta AA, et al. Expression of nuclear factor-κB in human astrocytomas: Relation to pI κ Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008; 39: 1143-1152.
20. Angileri FF, Aguennouz M, Conti A, et al. Nuclear factor-κB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 2008; 112: 2258-2266.
21. Xie TX, Xia Z, Zhang N, et al. Constitutive NF-κB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol Rep 2010; 23: 725-732.
22. Bhatia S, Hamid O, Pavlick AC, et al. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study. J Clin Oncol 2011; 29: Abstr 8529.
23. Erba H, Swords R, DeAngelo D, et al. MLN4924, a novel investigational NEDD8-activating enzyme (NAE) inhibitor, in adult patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndromes (MDS): Results from a phase 1 study. Haematologica 2011; 96: 28 (Abstr #0068).
24. Kauh JS, Shapiro G, Cohen RB, et al. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. J Clin Oncol 2011; 29: Abstr 3013.
25. Shah J, Jakubowiak A, O'Connor O, et al. MLN4924, a novel NAE inhibitor in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL): Phase 1 dose-escalation study. Haematologica 2010; 95: 160 (Abstr 0394).
26. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
27. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679.
28. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
29. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
30. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-716.
31. Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: Treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 2003; 21: 1782-1789.
32. Olson MR, Donaldson SS. Treatment of pediatric Hodgkin lymphoma. Curr Treat Options Oncol 2008; 9: 81-94.